560 related articles for article (PubMed ID: 30131604)
1. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.
Crawford ED; Heidenreich A; Lawrentschuk N; Tombal B; Pompeo ACL; Mendoza-Valdes A; Miller K; Debruyne FMJ; Klotz L
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):24-38. PubMed ID: 30131604
[TBL] [Abstract][Full Text] [Related]
2. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
3. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
4. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
5. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
6. Contemporary role of androgen deprivation therapy for prostate cancer.
Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
[TBL] [Abstract][Full Text] [Related]
7. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
[TBL] [Abstract][Full Text] [Related]
8. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
9. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
10. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
Shore ND; Morgans AK; Ryan CJ
Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
[TBL] [Abstract][Full Text] [Related]
11. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
12. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
14. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Nishiyama T
Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
[TBL] [Abstract][Full Text] [Related]
15. Testosterone in prostate cancer: the Bethesda consensus.
Djavan B; Eastham J; Gomella L; Tombal B; Taneja S; Dianat SS; Kazzazi A; Shore N; Abrahamsson PA; Cheetham P; Moul J; Lepor H; Crawford ED
BJU Int; 2012 Aug; 110(3):344-52. PubMed ID: 22129242
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
[TBL] [Abstract][Full Text] [Related]
18. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
19. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
20. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
